1OL0

Crystal structure of a camelised human VH


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.180 
  • R-Value Work: 0.154 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Crystal Structure of a Human Vh: Requirements for Maintaining a Monomeric Fragment

Dottorini, T.Vaughan, C.K.Walsh, M.A.Losurdo, P.Sollazzo, M.

(2004) Biochemistry 43: 622

  • DOI: 10.1021/bi035800b

  • PubMed Abstract: 
  • The variable domain of dromedary immunoglobulins comprises only the heavy chain and is missing the light-chain variable domain. This single domain is sufficient for antigen recognition and binding-half that required by other mammals. Human antibody-V ...

    The variable domain of dromedary immunoglobulins comprises only the heavy chain and is missing the light-chain variable domain. This single domain is sufficient for antigen recognition and binding-half that required by other mammals. Human antibody-VHs have previously been camelized to be soluble stable fragments that retain antigen binding. Such engineered VHH are of interest in drug development, since they are nonimmunogenic, and in other biotechnology applications. We present the structure of a camelized human antibody fragment (cVH), which is a competitive and reversible inhibitor of the NS3 serine protease of the hepatitis C virus (HCV). In solution, this cVH undergoes a concentration-dependent monomer-dimer equilibrium. The structure confirms the minimum mutational requirements of the VL-binding face. The fragment also suggests a means by which the observed dimerization occurs, highlighting the importance of the composition of the CDR3 in maintaining a truly camelized VH.


    Related Citations: 
    • Affinity Selection of a Camelized V(H) Domain Antibody Inhibitor of Hepatitis C Virus Ns3 Protease
      Martin, F.,Volpari, C.,Steinkuhler, C.,Dimasibrunetti, M.,Biasiol, G.,Altamura, S.,Cortese, R.,Defrancesco, R.,Sollazzo, M.
      (1997) Protein Eng. 10: 607
    • Inhibition of the Hepatitis C Virus Ns3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes
      Dimarco, S.,Rizzi, M.,Volpari, C.,Walsh, M.A.,Narjes, F.,Colarusso, S.,Defrancesco, R.,Matassa, V.G.,Sollazzo, M.
      (2000) J.Biol.Chem. 275: 7152
    • Rearrangement of the Former Vl Interface in the Solution Structure of a Camelised, Single Antibody Vh Domain
      Riechmann, L.
      (1996) J.Mol.Biol. 259: 957


    Organizational Affiliation

    Istituto di Ricerche di Biologia Molecolare, Crystallography Unit, Via Pontina km 30600, 00040 Pomezia (Rm), Italy.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
IMMUNOGLOBULIN G
A, B
121N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A, B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
GOL
Query on GOL

Download SDF File 
Download CCD File 
A, B
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
MSE
Query on MSE
A, B
L-PEPTIDE LINKINGC5 H11 N O2 SeMET
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.180 
  • R-Value Work: 0.154 
  • Space Group: P 32 2 1
Unit Cell:
Length (Å)Angle (°)
a = 75.300α = 90.00
b = 75.300β = 90.00
c = 101.780γ = 120.00
Software Package:
Software NamePurpose
DENZOdata reduction
AMoREphasing
REFMACrefinement
SCALEPACKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2004-01-22
    Type: Initial release
  • Version 1.1: 2011-05-08
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance